Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Medincell S.a. buy melinda

Start price
€9.76
16.09.21 / 50%
Target price
€11.00
16.09.22
Performance (%)
-10.55%
End price
€8.73
15.04.22
Summary
This prediction ended on 15.04.22 with a price of €8.73. The prediction for Medincell S.a. disappointed with a performance of -10.55%. melinda has a follow-up prediction for Medincell S.a. where he still thinks Medincell S.a. is a Buy. melinda has 50% into this prediction
Performance without dividends (%)
Name 1w 1m 1y
Medincell S.a. - - -
iShares Core DAX® -1.670% -1.001% 10.864%
iShares Nasdaq 100 -4.184% -1.145% 37.458%
iShares Nikkei 225® -4.967% -5.783% 18.828%
iShares S&P 500 -2.834% -0.572% 25.875%

According to melinda what are the pros and cons of Medincell S.a. for the foreseeable future?

Pros
Could be worthwhile Investment >10% per year
Cons

Comments by melinda for this prediction

In the thread Medincell S.a. diskutieren
Prediction Buy
Perf. (%) -10.55%
Target price 11.000
Change
Ends at

Buy mit Kursziel 11,0

In the thread Trading Medincell S.a.
Prediction Buy
Perf. (%) -10.55%
Target price 11.000
Change
Ends at 16.09.22

Buy beendet

Current prediction by melinda for Medincell S.a.

buy
Medincell S.a.

Start price
Target price
Perf. (%)
€8.18
15.01.24
€10.00
15.01.25
35.45%
16:35

Could be worthwhile Investment >10% per year

Stopped prediction by melinda for Medincell S.a.

buy
Medincell S.a.

Start price
Target price
Perf. (%)
€5.20
06.09.22
-
06.09.23
34.04%
07.09.23

Could be worthwhile Investment >10% per year
buy
Medincell S.a.

Start price
Target price
Perf. (%)
€8.73
15.04.22
-
15.04.23
-28.41%
20.04.22

Could be worthwhile Investment >10% per year
buy
Medincell S.a.

Start price
Target price
Perf. (%)
€10.14
03.09.21
€12.00
03.09.22
-3.75%
16.09.21

Could be worthwhile Investment >10% per year